Pfizer's OTC, Nutritional Businesses Could Be Looking For A New Home
This article was originally published in The Tan Sheet
Executive Summary
Pfizer's consumer and nutritional businesses soon may be for sale, but the timing may not be right for the most likely buyers, market analysts say.
You may also be interested in...
Pfizer Likes Consumer Business Right Where It Is, Or Eventually Could Be
Driven by US sales of Nexium 24HR and Advil, Pfizer's fiscal 2016 first-quarter consumer product revenues increased 2% to $822m. CEO Ian Read says Pfizer is open to adding to or selling off its consumer business, but currently likes it just where it is.
Pfizer Likes Consumer Business Right Where It Is, Or Eventually Could Be
Driven by US sales of Nexium 24HR and Advil, Pfizer's fiscal 2016 first-quarter consumer product revenues increased 2% to $822m. CEO Ian Read says Pfizer is open to adding to or selling off its consumer business, but currently likes it just where it is.
J&J’s Problems, Pfizer’s Options And Switch Outlook Top “The Tan Sheet” Topics In 2011
Readers of “The Tan Sheet” in 2011 showed the most interest in stories about Johnson & Johnson’s OTC quality issues, Pfizer’s consumer business maneuvers and Rx-to-OTC switch outlooks. Other hot topics included omega-3 drug development, supplement GMP strategies and state pseudoephedrine laws.